Modus Therapeutics Holding AB (99Z) Price & Analysis

0 Followers

99Z Stock Chart & Stats

€0.03

>-€0.01(-1.57%)

At close: Jan 08 4:00 PM EST

€0.03

>-€0.01(-1.57%)

Day’s Range― - ―

52-Week Range€0.01 - €0.04

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€5.98M

Enterprise Value€39.62

Total Cash (Recent Filing)€12.49M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta2.24

Next Earnings

Nov 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.18

Shares Outstanding168,701,800

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.10

Price to Sales (P/S)0.00

P/FCF Ratio-1.05

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.01

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero debt reduces interest obligations and leverage-related financial risk, giving Modus greater flexibility while it advances its development programs. This conservative capital structure can help preserve resilience during periods when external funding is needed, even though it does not eliminate the company’s cash requirements.

Improved Equity BaseThe materially stronger equity position indicates that capital has been raised and the balance sheet has improved from prior periods. A larger equity base provides additional support for ongoing research and development and may improve the company’s ability to pursue milestones before requiring further financing.

Free Cash Flow ImprovementFree cash flow improved relative to 2025, providing a modest indication that cash performance is moving in a better direction. While the company remains far from self-funding, sustaining this improvement could moderate the pace of deterioration and extend the time available to advance its pipeline.

Bears Say

Pre-revenue Business ModelThe absence of commercial revenue means Modus currently lacks an operating income stream to fund research, administration, and development activities. Near- and medium-term progress therefore depends on advancing drug candidates toward future commercialization, licensing, or other financing events rather than established customer demand.

Persistent Operating LossesLarge operating and net losses show that current spending materially exceeds any inflows and that the company has not yet demonstrated operating leverage. Continued losses can reduce the equity cushion over time and require management to secure additional capital before the pipeline can generate commercial returns.

Ongoing Cash Funding DependenceSustained negative operating and free cash flow confirms that Modus is consuming capital to maintain its development-stage operations. Because cash burn has not stabilized, the company remains dependent on future equity financing or other external funding, creating an ongoing constraint on execution and financial flexibility.

99Z FAQ

What was Modus Therapeutics Holding AB’s price range in the past 12 months?

Modus Therapeutics Holding AB lowest stock price was €0.01 and its highest was €0.04 in the past 12 months.

What is Modus Therapeutics Holding AB’s market cap?

Modus Therapeutics Holding AB’s market cap is €5.98M.

When is Modus Therapeutics Holding AB’s upcoming earnings report date?

Modus Therapeutics Holding AB’s upcoming earnings report date is Nov 24, 2026 which is in 65 days.

How were Modus Therapeutics Holding AB’s earnings last quarter?

Modus Therapeutics Holding AB released its earnings results on Aug 26, 2026. The company reported -€0.003 earnings per share for the quarter.

Is Modus Therapeutics Holding AB overvalued?

According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Modus Therapeutics Holding AB pay dividends?

Modus Therapeutics Holding AB does not currently pay dividends.

What is Modus Therapeutics Holding AB’s EPS estimate?

Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Modus Therapeutics Holding AB have?

Modus Therapeutics Holding AB has 168,701,800 shares outstanding.

What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?

Modus Therapeutics Holding AB reported an EPS of -€0.003 in its last earnings report. Following the earnings report the stock price went down -4.545%.

Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?

Currently, no hedge funds are holding shares in DE:99Z

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Modus Therapeutics Holding AB

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.